The role of co-signaling molecules in psoriasis and their implications for targeted treatment

S Liu, J Xu, J Wu - Frontiers in Pharmacology, 2021 - frontiersin.org
Psoriasis is a chronic, systemic immune-mediated inflammatory disease manifesting in the
skin, joint or both. Co-signaling molecules are essential for determining the magnitude of the …

An update for the clinician on biologics for the treatment of psoriatic arthritis

MS Chimenti, A D'Antonio, P Conigliaro… - … : Targets and Therapy, 2020 - Taylor & Francis
Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy typically associated with
psoriasis (PsO). The pathogenesis is strictly related to the association among the presence …

Consensus statements for pharmacological management, monitoring of therapies, and comorbidity management of psoriatic arthritis in the United Arab Emirates

KA Alnaqbi, S Hannawi, R Namas… - International Journal …, 2022 - Wiley Online Library
Abstract Objective Psoriatic arthritis (PsA), a chronic inflammatory disease characterized by
heterogeneous clinical manifestations, substantially impacts the quality of life of affected …

Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort

FM Colella, G Zizzo, V Parrino, MT Filosa… - Advances in …, 2023 - SciELO Brasil
Background Secukinumab has shown high efficacy in randomized controlled trials in both
ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Here, we investigated its real-life …

Pharmacotherapeutic management of psoriatic disease: addressing psoriatic Arthritis and cutaneous manifestations

RC Yi, HY Gantz, SC Shah, SK Moran… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Psoriasis and psoriatic arthritis (PsA) are interrelated autoimmune conditions
sharing similar genetic and immunological pathways. PsA often develops within 10 years of …

Biological therapy for psoriatic arthritis: current state and future perspectives

D Boboryko, J Olejnik-Wojciechowska… - Rheumatology …, 2024 - Springer
Psoriatic arthritis is a medical condition that lies at the intersection of various fields of
medicine, and its therapy always requires a comprehensive, holistic approach. Biological …

Abatacept for the treatment of psoriatic arthritis

E Lubrano, S Scriffignano… - Expert Review of Clinical …, 2018 - Taylor & Francis
ABSTRACT Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory disease
characterized by the presence of psoriasis, arthritis, and enthesitis, with the association of …

Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial

IB McInnes, G Ferraccioli, MA d'Agostino, M Le Bars… - RMD open, 2019 - rmdopen.bmj.com
Objective This post hoc analysis of the phase III Active PSoriaTic Arthritis RAndomizEd TriAl
(ASTRAEA) evaluated the effect of baseline body mass index (BMI) on subsequent …

Measuring the T‐cell down‐regulation of TCR‐zeta, ZAP‐70 and CD28 in arthritis patients: An old tool for new biomarkers

G Zizzo, M De Santis, S Bosello… - European Journal of …, 2019 - Wiley Online Library
Low T‐cell receptor (TCR)/CD28 signaling lymphocytes are expanded in arthritis. We asked
whether the down‐expression of TCR‐related molecules correlates with specific arthritis …

Recommendations of the Mexican College of Rheumatology for the management of psoriatic arthritis

J Casasola-Vargas, D Flores-Alvarado… - … Clínica (English Edition), 2021 - Elsevier
Psoriatic arthritis is a chronic systemic inflammatory disease that affects the skin,
musculoskeletal structures and other organs and systems compromising functionality …